Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.
Papakonstantinou N, Ntoufa S, Chartomatsidou E, Kotta K, Agathangelidis A, Giassafaki L, Karamanli T, Bele P, Moysiadis T, Baliakas P, Sutton LA, Stavroyianni N, Anagnostopoulos A, Makris AM, Ghia P, Rosenquist R, Stamatopoulos K. Papakonstantinou N, et al. Oncotarget. 2016 Jun 14;7(24):35946-35959. doi: 10.18632/oncotarget.9371. Oncotarget. 2016. PMID: 27191993 Free PMC article.
DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy.
Tsagiopoulou M, Papakonstantinou N, Moysiadis T, Mansouri L, Ljungström V, Duran-Ferrer M, Malousi A, Queirós AC, Plevova K, Bhoi S, Kollia P, Oscier D, Anagnostopoulos A, Trentin L, Ritgen M, Pospisilova S, Stavroyianni N, Ghia P, Martin-Subero JI, Pott C, Rosenquist R, Stamatopoulos K. Tsagiopoulou M, et al. Among authors: papakonstantinou n. Clin Epigenetics. 2019 Dec 2;11(1):177. doi: 10.1186/s13148-019-0783-1. Clin Epigenetics. 2019. PMID: 31791414 Free PMC article.
Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.
Chartomatsidou E, Ntoufa S, Kotta K, Rovida A, Akritidou MA, Belloni D, Ferrero E, Trangas T, Stavroyianni N, Anagnostopoulos A, Rosenquist R, Ghia P, Papakonstantinou N, Stamatopoulos K. Chartomatsidou E, et al. Among authors: papakonstantinou n. Blood Adv. 2019 Jun 25;3(12):1891-1896. doi: 10.1182/bloodadvances.2018030262. Blood Adv. 2019. PMID: 31227476 Free PMC article.
Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8.
Gounari M, Ntoufa S, Apollonio B, Papakonstantinou N, Ponzoni M, Chu CC, Rossi D, Gaidano G, Chiorazzi N, Stamatopoulos K, Ghia P. Gounari M, et al. Among authors: papakonstantinou n. Blood. 2015 Jun 4;125(23):3580-7. doi: 10.1182/blood-2014-09-603217. Epub 2015 Apr 21. Blood. 2015. PMID: 25900981 Free PMC article. Clinical Trial.
Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia.
Papakonstantinou N, Ntoufa S, Tsagiopoulou M, Moysiadis T, Bhoi S, Malousi A, Psomopoulos F, Mansouri L, Laidou S, Papazoglou D, Gounari M, Pasentsis K, Plevova K, Kuci-Emruli V, Duran-Ferrer M, Davis Z, Ek S, Rossi D, Gaidano G, Ritgen M, Oscier D, Stavroyianni N, Pospisilova S, Davi F, Ghia P, Hadzidimitriou A, Belessi C, Martin-Subero JI, Pott C, Rosenquist R, Stamatopoulos K. Papakonstantinou N, et al. Int J Cancer. 2019 Jun 1;144(11):2695-2706. doi: 10.1002/ijc.31999. Epub 2019 Jan 15. Int J Cancer. 2019. PMID: 30447004
102 results